Torres-Peña, José DavidPérez-Belmonte, Luis MFuentes-Jiménez, FranciscoLópez Carmona, Mª DoloresPérez-Martinez, PabloLópez-Miranda, JoséCarrasco Sánchez, Francisco JavierVargas Núñez, Juan AntonioDel Corral Beamonte, EstherMagallanes Gamboa, Jeffrey OskarGonzález García, AndrésGonzález Moraleja, JulioCortés Troncoso, AndrésTaboada Martínez, María LuisaDel Fidalgo Montero, María Del PilarSeguí Ripol, José MiguelGil Sánchez, RicardoAlegre González, DianaBoixeda, RamonCortés Rodríguez, BegoñaEna, JavierGarcía García, Gema MaríaVentura Esteve, AnaRamos Rincón, José ManuelGómez-Huelgas, RicardoSEMI-COVID-19 Network2025-01-072025-01-072021-03-29https://hdl.handle.net/10668/27994The impact of statins on COVID-19 outcomes is important given the high prevalence of their use among individuals at risk for severe COVID-19. Our aim is to assess whether patients receiving chronic statin treatment who are hospitalized with COVID-19 have reduced in-hospital mortality if statin therapy is maintained during hospitalization. This work is a cross-sectional, observational, retrospective multicenter study that analyzed 2921 patients who required hospital admission at 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics and COVID-19 disease outcomes between patients receiving chronic statin therapy who maintained this therapy during hospitalization versus those who did not. Propensity score matching was used to match each statin user whose therapy was maintained during hospitalization to a statin user whose therapy was withdrawn during hospitalization. After propensity score matching, continuation of statin therapy was associated with lower all-cause mortality (OR 0.67, 0.54-0.83, p Patients previously treated with statins who are hospitalized for COVID-19 and maintain statin therapy during hospitalization have a lower mortality rate than those in whom therapy is withdrawn. In addition, statin therapy was associated with a decreased probability that patients with COVID-19 will develop AKI, ARDS, or sepsis and decreases the need for IMV.enAgedAged, 80 and overCOVID-19Cross-Sectional StudiesFemaleHospital MortalityHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPropensity ScoreRetrospective StudiesRisk AssessmentSARS-CoV-2Spainresearch article33782908open access10.1007/s40265-021-01498-x1179-1950PMC8006631https://link.springer.com/content/pdf/10.1007/s40265-021-01498-x.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8006631/pdf